The most common adaptation of TERT promoter-driven gene therapy simply expresses various therapeutic moieties (anticancer transgenes, miRNA, or the CRISPR/Cas9 system) in a cancer-selective manner [57,58,59,60,61,62]. This evidence concerns the gene TERT and cancer.